Morepen Laboratories Limited
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
What Morepen files
- Others58
- Important37
- Updates32
- Investor Meet9
- Board Meeting8
- PPTs6
Morepen Laboratories' board approved Q1 FY27 consolidated financial results: revenue Rs 570.13 Cr, net profit Rs 56.35 Cr (EPS Rs 1.03). They set Sep 19, 2026, as record date for the FY26 dividend and extended the Medical Devices business hive-off timeline. Mr. Sushil Suri's reappointment as CMD for three years...
Morepen Labs approved consolidated financial results for FY26 with a net profit of Rs 94.88 Cr. A final dividend of Re 0.20/share was proposed. The board also approved a revised agreement to hive off its Medical Devices business to a subsidiary for Rs 197.10 Cr and re-appointed Cost Auditors.
Morepen Labs' board met on Feb 10, 2026, and approved consolidated financial results for the quarter and nine months ended Dec 31, 2025. Q3 revenue was ₹487.97 Cr with a ₹27.50 Cr profit. For the nine months, revenue hit ₹1333.82 Cr, with profit at ₹79.95 Cr.
Morepen Labs' board approved financial results for the quarter and half-year. Consolidated Net Profit for H1 FY26 was Rs 51.62 Cr. The company booked a Rs 25.83 Cr exceptional gain from Dr. Morepen Ltd ceasing to be a subsidiary.
Morepen Labs has announced a board meeting on August 6, 2025. The company reported consolidated financial results for the quarter ended June 30, 2025: total income Rs. 429.65 Cr, net profit Rs. 11.41 Cr. The board set August 30, 2025, as record date for the FY25 final dividend, pending shareholder...